Comparing GATT-Patch and SURGICEL® for controlling bleeding in liver and gallbladder surgery

A Prospective, Multicenter, Randomized Clinical Investigation Evaluating GATT-Patch for Hemostasis During Minimally Invasive Liver and Gallbladder Surgery

This study is testing whether a new product called GATT-Patch works better than SURGICEL® to help control bleeding during liver and gallbladder surgeries.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 50 (estimated)
• Ages: 22 Years and up
• Sex: All
• Sponsor: GATT Technologies BV (Industry-sponsored)
• Locations: 6 sites (Los Angeles, California and 5 other locations)
• Trial ID: NCT05900037 on ClinicalTrials.gov

What this trial studies

This clinical investigation aims to evaluate the effectiveness of GATT-Patch compared to SURGICEL® Original in managing mild to moderate bleeding during minimally invasive surgeries on the liver and gallbladder. It is a pre-market, prospective, randomized, multicenter study where participants will be assigned to receive either GATT-Patch or SURGICEL® Original. The study focuses on patients undergoing elective robotic or laparoscopic surgeries and aims to identify the best hemostatic agent for controlling intraoperative bleeding. The results will help determine the clinical performance of GATT-Patch in a surgical setting.

Who should consider this trial

Good fit: Ideal candidates are adults aged 22 and older scheduled for elective minimally invasive liver or gallbladder surgery with identified bleeding sites.

Not a fit: Patients who are not undergoing minimally invasive surgery or those with bleeding that can be managed by conventional means may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a more effective hemostatic solution for patients undergoing minimally invasive liver and gallbladder surgeries.

How similar studies have performed: Other studies have shown success with similar hemostatic agents, indicating potential for GATT-Patch to be an effective alternative.

Eligibility criteria

Inclusion Criteria:

* Subject is scheduled to undergo elective minimally invasive (robotic or laparoscopic) surgery on the liver, including cholecystectomy
* Subject is willing and able to give written informed consent for the clinical investigation participation
* Subjects is 22 years of age or older at the time of enrollment; and
* Subject has been informed of the nature of the clinical investigation.

A subject must meet all of the following intra-operative inclusion criteria to be enrolled into the clinical investigation:

* Subject undergoes a fully minimally invasive surgical approach without the use of a hand port at the time of randomization and application of the patch;
* Subject in whom the Investigator is able to identify a target bleeding site at the liver resection plane for which any applicable conventional means for hemostasis (e.g. suture, ligature or cautery) are ineffective or impractical, and the choice is made to use a hemostatic agent to stop the bleeding
* Pressure on the surface of the hemostatic agent can be applied with the minimally invasive instruments to achieve hemostasis
* Subject has a target bleeding site with a SBSS of 1, 2, or 3 (e.g. reflecting minimal, mild or moderate bleeding severities)

Exclusion Criteria:

* The target bleeding site is from a large defect in an artery or vein that requires vascular reconstruction with maintenance of vessel patency
* Subject is scheduled to undergo surgery on organs other than the liver and its associated biliary and vascular system
* Subject is scheduled to undergo a staged liver surgery procedure (e.g., Associating Liver Partition and Portal vein ligation for Staged hepatectomy \[ALPPS\])
* Subject is taking multiple antithrombotic therapies in therapeutic dosage up to the time of surgery, but allowing exclusive use of acetylsalicylic acid
* Subject has platelet count \<100 x 109/L, an activated partial thrombin time of \>100s, or international normalized ratio \>2.5
* Subject has a total bilirubin level of ≥2.5 mg/dl
* Subject is pregnant, planning on becoming pregnant or actively breastfeeding during the 3-month follow-up period
* Subject has a known hypersensitivity to brilliant blue (FD\&C Blue #1), porcine gelatin
* Subject who has religious objections to receiving products containing porcine
* Subject has an active or suspected infection at the bleeding site
* Subject in whom the investigational device will be used at the site of a synthetic graft or patch implant
* Subject has a life expectancy of less than 3 months
* Subject has a documented severe congenital or acquired immunodeficiency
* Subject has had or has planned to receive any organ transplantation
* Subject undergoes surgery with the indication of being a living liver donor
* Subject is currently participating or has participated in another clinical investigation within the past 30 days that may affect the endpoints of the study, such as trials related to the surgical procedure and anti-coagulation
* Subject is not appropriate for inclusion in the clinical investigation, per the medical opinion of the Investigator
* Subject has any incidental (pre- and peri-operative) findings deemed by the Investigator to potentially jeopardize the safety or welfare of the subject

Where this trial is running

Los Angeles, California and 5 other locations

• University of Southern California — Los Angeles, California, United States (Recruiting)
• Washington University — Saint Louis, Missouri, United States (Recruiting)
• Capital Health — Pennington, New Jersey, United States (Recruiting)
• Weill-Cornell — New York, New York, United States (Recruiting)
• Atrium Health — Charlotte, North Carolina, United States (Not_yet_recruiting)
• Intermountain Healthcare — Murray, Utah, United States (Recruiting)

Study contacts

• Study coordinator: Stuart Head, MD PhD

Conditions Intraoperative Bleeding; Liver Diseases; Gallbladder Diseases; Hemorrhage, Surgical; Hemostatic patch; GATT-Patch; SURGICEL® Original; Liver surgery